HSBC Holdings
TSHA icon

HSBC Holdings’s Taysha Gene Therapies TSHA Stock Holding History

HSBC Holdings’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,257
Closed -$27.7K – 3247
2025
Q1 		$27.7K Sell
20,257
-134
-0.7% -$224 ﹤0.01% 2955
2024
Q4 		$35.6K Buy
20,391
+8,076
+66% +$16.8K ﹤0.01% 3021
2024
Q3 		$24.8K Buy
+12,315
New +$27K ﹤0.01% 2935
2022
Q4 		– Sell
-16,570
Closed -$32K – 3197
2022
Q3 		$32K Hold
16,570
– – ﹤0.01% 2852
2022
Q2 		$63K Buy
+16,570
New +$65.7K ﹤0.01% 3111

Other funds holding TSHA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HSBC Holdings's TSHA Position: Q2 2025 in Review

HSBC Holdings sold out of Taysha Gene Therapies (TSHA) in Q2 2025, closing a stake of 20,257 shares — an estimated $27.7K sold.

HSBC Holdings first reported a position in TSHA in Q2 2022 and held it in 5 quarters. The position peaked at $63K in Q2 2022. 150 funds tracked by Wall St. Rank hold TSHA as of Q2 2025.

  • HSBC Holdings reported no remaining Taysha Gene Therapies position as of Q2 2025 after selling out during the quarter.
  • HSBC Holdings sold 20,257 Taysha Gene Therapies shares in Q2 2025, an estimated $27.7K.
  • HSBC Holdings first reported a position in Taysha Gene Therapies in Q2 2022 and held it in 5 quarters.
  • HSBC Holdings's Taysha Gene Therapies position peaked at $63K in Q2 2022.
  • 150 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2025.

Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.